Estimation of Age Composition using Maximum Likelihood from Length Frequency Distribution of Nile Tilapia (Oreochromis niloticus) in Lake Tana, Ethiopia

Estimation of age composition of fish using Length frequency distribution is common if there is no aging of individual fish using otoliths or tag and recapture methods. It can be done by using maximum likelihood. The objectives of this study, therefore, to estimate age compositions; and the Von Bertalanffy growth coefficient and asymptotic length of the Nile tilapia stock. Available length-frequency data from Bahirdar Fisheries and Other Aquatic Life Research Center’s annual progressive reports for Nile tilapia fishery was compiled into 63 groups with  0.5-cm size classes (11-11.5 cm to 41.5-42cm). Length-frequency observations consisted of the actual number of catch at length  measured of the specious by year was used for this study. Estimation of age composition in to age cohorts and estimation of the proportions each age cohort was done using maximum likelihood. The number of age classes of the stock was selected using an index of AIC.  According the result of minimum AIC, a stock having three cohorts was selected with the proportion in the population of 0.14, 0.285, and 0.875 for the 1st, 2nd and 3rd cohorts, respectively. It was found also that this estimation is statistically significant at a significant level of less than 1%. The Von Bertalanffy growth coefficient and asymptotic length were also estimated. The growth parameter measured in the change in average length per cohort was 0.435cm and highly significant; and the asymptotic fish length was 44.11 cm. Keywords: length frequency distribution, Maximum Likelihood, , age composition, Nile tilapia,  asymptotic length, growth parameter

Study on the prevalence of ectoparasite infestation of ruminanats in and around Kombolcha and damage to fresh goat pelts and wet blue (pickled) skin at Kombolch Tannary, Northestern Ethiopia

An attempt was made to study the prevalence of ectoparasite damage on live cattle, sheep and goats in and around Kombolcha town and on raw goat skin to assess their skin defect on processed wet-blue (pickled) skins at Kombolcha tannery, south wollo zone, North-Eastern Ethiopia. A total of 240 cattle, 175 sheep, 66 goats, were used to study the prevalence of ectoprasites on live animals as well as 344 fresh goat pelts and pickled (wet-blue) goat skins were used to assess skin defects. The result obtained from live cattle demonstrated a high prevalence of Amblyomma (28.33%) followed by Sarcoptes scabiei (23.75%), Boophilus (11.25%) Demodex (9.58%), Psoroptes (0.4 %), respevtively. The prevalence of ectoprasite infestation of live sheep revealed Mellophagus ovinus (sheep ked) (32.57%), Bovicola ovis (22.28%), Amblyomma spp (12.57%), Sarcoptes scabiei (14.28 %), Ctenocephaliedes spp (8.57%), Demodex (6.85%), Linognathus africanus (6.28%) and Boophilus spp (4%). The result from goats demonstrates a high prevalence of Sarcoptes scabiei (30.3%) followed by Linognathus stenopsis (9.09%), Amblyomma (4.54%), Ctenocephalides spp (3.03%), Bovicola caprea (1.51%) and Demodex (1.51%) in that order. Result obtained from fresh goats pelts revealed an over all high prevalence of Sacoptes scabie (53.29%) followed by Linognathus stenopsis (9.88%), Bovicola caprae (2.08%) and Demodex (2.08%). Examination of pickled (wet-blue) skins from follow-up skins show a high prevalence of scratch (74.25%) followed by “Ekek” (68.56%), scar (67.06%), processing defect (28.44%). “Ekek” (Typical scatter type cockle) was found to show a significant (

Prevalence and characterization of antimicrobial resistance among gram-negative bacteria isolated from febrile hospitalized patients in central Ethiopia

BACKGROUND: Infectious diseases are among the leading causes of death in many low-income countries, such as Ethiopia. Without reliable local data concerning causative pathogens and antimicrobial resistance, empiric treatment is suboptimal. The objective of this study was to characterize gram-negative bacteria (GNB) as pathogens and their resistance pattern in hospitalized patients with infections in central Ethiopia. METHODS: Patients ≥ 1 year of age with fever admitted to the Asella Referral and Teaching Hospital from April 2016 to June 2018 were included. Blood and other appropriate clinical specimens were collected and cultured on appropriate media. Antibiotic susceptibility testing (AST) was performed using the Kirby–Bauer method and VITEK® 2. Species identification and detection of resistance genes were conducted using MALDI-ToF MS (VITEK® MS) and PCR, respectively. RESULTS: Among the 684 study participants, 54.2% were male, and the median age was 22.0 (IQR: 14–35) years. Blood cultures were positive in 5.4% (n = 37) of cases. Among other clinical samples, 60.6% (20/33), 20.8% (5/24), and 37.5% (3/8) of swabs/pus, urine and other body fluid cultures, respectively, were positive. Among 66 pathogenic isolates, 57.6% (n = 38) were GNB, 39.4% (n = 26) were gram-positive, and 3.0% (n = 2) were Candida species. Among the isolated GNB, 42.1% (16/38) were Escherichia coli, 23.7% (9/38) Klebsiella pneumoniae and 10.5% (4/38) Pseudomonas aeruginosa. In total, 27/38 gram-negative isolates were available for further analysis. Resistance rates were as follows: ampicillin/sulbactam, 92.6% (n = 25); cefotaxime, 88.9% (n = 24); ceftazidime, 74.1% (n = 20); cefepime, 74.1% (n = 20); gentamicin, 55.6% (n = 15); piperacillin/tazobactam, 48.1% (n = 13); meropenem, 7.4% (n = 2); and amikacin, 3.7% (n = 1). The bla(NDM-1) gene was detected in one K. pneumoniae and one Acinetobacter baumannii isolate, which carried an additional bla(OXA-51) gene. The ESBL enzymes were detected in 81.5% (n = 22) of isolates as follows: TEM, 77.2% (n = 17); CTX-M-1 group, 68.2% (n = 15); SHV group, 27.3% (n = 6); and CTX-M-9 group, 9.1% (n = 2). Based on the in vitro antimicrobial susceptibility results, empiric treatment initiated in 13 of 18 (72.2%) patients was likely ineffective. CONCLUSION: We report a high prevalence of ESBL-producing bacteria (81.5%) and carbapenem resistance (7.4%), with more than half of GNB carrying two or more ESBL enzymes resulting in suboptimal empiric antibiotic therapy. These findings indicate a need for local and national antimicrobial resistance surveillance and the strengthening of antimicrobial stewardship programs

A multicentric evaluation of dipstick test for serodiagnosis of visceral leishmaniasis in India, Nepal, Sri Lanka, Brazil, Ethiopia and Spain

Author Correction: A multicentric evaluation of dipstick test for serodiagnosis of visceral leishmaniasis in India, Nepal, Sri Lanka, Brazil, Ethiopia and Spain PMID: 33574485Visceral leishmaniasis (VL) is one of the leading infectious diseases affecting developing countries. Colloidal gold-based diagnostic tests are rapid tools to detect blood/serum antibodies for VL diagnosis. Lack of uniformity in the performance of these tests in different endemic regions is a hurdle in early disease diagnosis. This study is designed to validate a serum-based dipstick test in eight centres of six countries, India, Nepal, Sri Lanka, Brazil, Ethiopia and Spain with archived and fresh sera from 1003 subjects. The dipstick detects antibodies against Leishmania donovani membrane antigens (LAg). The overall sensitivity and specificity of the test with 95% confidence intervals were found to be 97.10% and 93.44%, respectively. The test showed good sensitivity and specificity in the Indian subcontinent (>95%). In Brazil, Ethiopia, and Spain the sensitivity and specificity of the dipstick test (83.78-100% and 79.06-100%) were better as compared to the earlier reports of the performance of rK39 rapid test in these regions. Interestingly, less cross-reactivity was found with the cutaneous form of the disease in Spain, Brazil, and Sri Lanka demonstrating 91.58% specificity. This dipstick test can therefore be a useful tool for diagnosing VL from other symptomatically similar diseases and against cutaneous form of leishmaniasis.S

Design and Analysis of Anomaly Detection and Mitigation Schemes for Distributed Denial of Service Attacks in Software Defined Network. An Investigation into the Security Vulnerabilities of Software Defined Network and the Design of Efficient Detection and Mitigation Techniques for DDoS Attack using Machine Learning Techniques

Software Defined Networks (SDN) has created great potential and hope to overcome the need for secure, reliable and well managed next generation networks to drive effective service delivery on the go and meet the demand for high data rate and seamless connectivity expected by users. Thus, it is a network technology that is set to enhance our day-to-day activities. As network usage and reliance on computer technology are increasing and popular, users with bad intentions exploit the inherent weakness of this technology to render targeted services unavailable to legitimate users. Among the security weaknesses of SDN is Distributed Denial of Service (DDoS) attacks. Even though DDoS attack strategy is known, the number of successful DDoS attacks launched has seen an increment at an alarming rate over the last decade. Existing detection mechanisms depend on signatures of known attacks which has not been successful in detecting unknown or different shades of DDoS attacks. Therefore, a novel detection mechanism that relies on deviation from confidence interval obtained from the normal distribution of throughput polled without attack from the server. Furthermore, sensitivity analysis to determine which of the network metrics (jitter, throughput and response time) is more sensitive to attack by introducing white Gaussian noise and evaluating the local sensitivity using feed-forward artificial neural network is evaluated. All metrics are sensitive in detecting DDoS attacks. However, jitter appears to be the most sensitive to attack. As a result, the developed framework provides an avenue to make the SDN technology more robust and secure to DDoS attacks

Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial

Visceral leishmaniasis (VL) is a parasitic disease with about 500,000 new cases each year and is fatal if untreated. The current standard therapy involves long courses, has toxicity and there is evidence of increasing resistance. New and better treatment options are urgently needed. Recently, the antibiotic paromomycin (PM) was tested and registered in India to treat this disease, but the same dose of PM monotherapy evaluated and registered in India was not efficacious in Sudan. This article reports the results of a clinical trial to test the effectiveness of injectable PM either alone (in a higher dose) or in combination with sodium stibogluconate (SSG) against the standard SSG monotherapy treatment in four East African countries—Sudan, Kenya, Ethiopia and Uganda. The study showed that the combination of SSG &PM was as efficacious and safe as the standard SSG treatment, with the advantages of being cheaper and requiring only 17 days rather than 30 days of treatment. In March 2010, a WHO Expert Committee recommended the use of the SSG & PM combination as a first line treatment for VL in East Africa

Geographical Variation in the Response of Visceral Leishmaniasis to Paromomycin in East Africa: A Multicentre, Open-Label, Randomized Trial

Visceral leishmaniasis (VL) is a fatal parasitic disease with 500,000 new cases each year according to WHO estimates. New and better treatment options are urgently needed in disease endemic areas due to the long courses, toxicity and development of resistance to current treatments. Recently, the antibiotic paromomycin was tested and registered in India to treat this disease. The current study describes a clinical trial to test the effectiveness of injectable paromomycin, either alone or in combination with the standard drug sodium stibogluconate in three East African countries—Sudan, Kenya and Ethiopia. The study showed that at the same paromomycin dose that was successfully used and registered in India, a far poorer outcome was obtained, particularly in Sudan, suggesting that there are either differences in the patients ability to respond to the drug or in the susceptibility of parasites in East Africa compared with those in India. However, no major safety concerns were noted with the treatment. Further research was initiated to see if a higher dose of paromomycin would perform better, especially in Sudan. The results of this and the performance of the combination arm will be reported later. Our study highlights the importance of considering geographical differences to treatment responses

Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: A systematic analysis for the global burden of disease study 2017

© 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license Background: Previous attempts to characterise the burden of chronic respiratory diseases have focused only on specific disease conditions, such as chronic obstructive pulmonary disease (COPD) or asthma. In this study, we aimed to characterise the burden of chronic respiratory diseases globally, providing a comprehensive and up-to-date analysis on geographical and time trends from 1990 to 2017. Methods: Using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, we estimated the prevalence, morbidity, and mortality attributable to chronic respiratory diseases through an analysis of deaths, disability-adjusted life-years (DALYs), and years of life lost (YLL) by GBD super-region, from 1990 to 2017, stratified by age and sex. Specific diseases analysed included asthma, COPD, interstitial lung disease and pulmonary sarcoidosis, pneumoconiosis, and other chronic respiratory diseases. We also assessed the contribution of risk factors (smoking, second-hand smoke, ambient particulate matter and ozone pollution, household air pollution from solid fuels, and occupational risks) to chronic respiratory disease-attributable DALYs. Findings: In 2017, 544·9 million people (95% uncertainty interval [UI] 506·9–584·8) worldwide had a chronic respiratory disease, representing an increase of 39·8% compared with 1990. Chronic respiratory disease prevalence showed wide variability across GBD super-regions, with the highest prevalence among both males and females in high-income regions, and the lowest prevalence in sub-Saharan Africa and south Asia. The age-sex-specific prevalence of each chronic respiratory disease in 2017 was also highly variable geographically. Chronic respiratory diseases were the third leading cause of death in 2017 (7·0% [95% UI 6·8–7·2] of all deaths), behind cardiovascular diseases and neoplasms. Deaths due to chronic respiratory diseases numbered 3 914 196 (95% UI 3 790 578–4 044 819) in 2017, an increase of 18·0% since 1990, while total DALYs increased by 13·3%. However, when accounting for ageing and population growth, declines were observed in age-standardised prevalence (14·3% decrease), age-standardised death rates (42·6%), and age-standardised DALY rates (38·2%). In males and females, most chronic respiratory disease-attributable deaths and DALYs were due to COPD. In regional analyses, mortality rates from chronic respiratory diseases were greatest in south Asia and lowest in sub-Saharan Africa, also across both sexes. Notably, although absolute prevalence was lower in south Asia than in most other super-regions, YLLs due to chronic respiratory diseases across the subcontinent were the highest in the world. Death rates due to interstitial lung disease and pulmonary sarcoidosis were greater than those due to pneumoconiosis in all super-regions. Smoking was the leading risk factor for chronic respiratory disease-related disability across all regions for men. Among women, household air pollution from solid fuels was the predominant risk factor for chronic respiratory diseases in south Asia and sub-Saharan Africa, while ambient particulate matter represented the leading risk factor in southeast Asia, east Asia, and Oceania, and in the Middle East and north Africa super-region. Interpretation: Our study shows that chronic respiratory diseases remain a leading cause of death and disability worldwide, with growth in absolute numbers but sharp declines in several age-standardised estimators since 1990. Premature mortality from chronic respiratory diseases seems to be highest in regions with less-resourced health systems on a per-capita basis. Funding: Bill & Melinda Gates Foundation